Feedback / Questions
laflunimus (AP-325) - Algiax
https://www.businesswire.com/news/home/20230530005069/en/Algiax-Pharmaceuticals-Announces-Positive-Interim-Analysis-of-Phase-2a-Study-with-Lead-Candidate-AP-325-in-Chronic-Neuropathic-Pain
May 30, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next